Shenzhen Binde Biotechnology Co., Ltd.

主要目的： 评价注射用AS1501在中国健康受试者中单次静脉注射给药的耐受性和安全性，为后期临床研究推荐合理的给药方案； 次要目的： （1）评价注射用AS1501在中国健康受试者中的药代动力学特征； （2）评价注射用AS1501在中国健康受试者中的免疫原性； 探索性目的： 初步探索注射用AS1501静脉注射给药前后血清中TRAIL表达水平的变化。

This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.

This is a study in which pancreatic cancer patients receive a immunotherapy with CART-meso cells administered at 3 days after one dose of cyclophosphamide. CART-meso cells are patients' own T cells lentivirally transduced to express anti-mesothelin scFv fused to TCRζ and 4-1BB costimulatory domains.The lymphodepletion with cyclophosphamide may prolong the persistence of CART cells.